BioBridgeX
Log inCompare quotes
CMC / Manufacturing

Process Development CDMOs

Free for buyersNeutral marketplace
Quick answer

Process development is the CMC work that turns a lab-scale recipe into a defined, repeatable manufacturing process: optimizing upstream and downstream unit operations, scaling up, and characterizing the process so it holds at GMP scale. You need it before clinical drug-substance batches. On BioBridgeX, buyers source and compare qualified CDMOs in one place.

Process Development CDMOs on BioBridgeX

We are qualifying and publishing Process Development CDMOs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is Process Development and when do you need it?

Process development is the bench-to-batch work that takes a molecule someone made once, at small scale, and turns it into a process you can run the same way, at a useful scale, with results you can predict. In a discovery or research lab a protein gets expressed in a few shake flasks and purified by hand, or an API is made on a route that works for grams. None of that survives contact with a clinical batch. Process development is where a CDMO defines the actual unit operations, sets the operating ranges, and proves the process gives you the yield, purity, and quality you can defend later.

You typically need it once you have a locked candidate and you are heading toward GMP material for the clinic, so it sits squarely in the CMC stage, usually feeding the IND-enabling and Phase 1 supply effort. For a biologic the work splits into upstream (cell culture or fermentation: media and feed strategy, bioreactor conditions, titer) and downstream (harvest, capture chromatography, polishing steps, viral clearance, ultrafiltration and diafiltration, final formulation). For a small-molecule API it is route selection and optimization, reaction conditions, crystallization and polymorph control, and impurity fate-and-purge. Different modality, same goal: a process that is reliable, scalable, and characterized well enough that the next batch is not a surprise.

The reason teams treat this stage seriously is that everything downstream inherits it. Your analytical methods, your control strategy, your stability program, and eventually your Module 3 filing all rest on the process you define here. Cut corners in process development and you pay for it in failed engineering runs, a tech transfer that does not reproduce, or a comparability headache when you scale for Phase 3. Get it right and the GMP batches that follow are far less likely to slip your clinical timeline.

What does a Process Development CDMO actually do?

A process development group does the experimental work that converts a candidate into a manufacturable process and the documentation behind it. The exact menu depends on modality, but the shape is consistent: optimize the steps, understand which parameters matter, lock a control strategy, and transfer the process cleanly to the manufacturing floor. Most of this can run non-GMP, since the point is to define and de-risk the process before you commit to expensive GMP runs.

What you are buying is process knowledge, not just hands. A strong group uses design of experiments (DoE) to map how critical process parameters drive critical quality attributes, runs scale-down models so a 2 to 5 liter bench bioreactor predicts behavior at 200 or 2000 liters, and builds the process characterization that supports your eventual control strategy and process validation. For an API, that same discipline shows up as reaction kinetics, impurity tracking, crystallization and polymorph studies, and a route that is safe and economical at scale.

  • Upstream development (biologics): cell line evaluation and fit, media and feed optimization, bioreactor scale-up, titer and productivity improvement, and harvest clarification.
  • Downstream development (biologics): chromatography capture and polish, viral inactivation and filtration, UF/DF, and aggregate and impurity removal to hit your purity target.
  • Process synthesis and optimization (small molecule): route scouting and selection, reaction optimization, crystallization and polymorph control, and impurity fate-and-purge studies.
  • Process characterization and DoE: identifying critical process parameters and quality attributes, defining proven acceptable ranges, and building the control strategy.
  • Scale-up and scale-down models: translating a bench process to pilot and engineering scale, with a representative scale-down model for later characterization.
  • Formulation and developability support, coordinated with analytical development so you can measure what you make.
  • Tech transfer: protocols, batch records, risk assessments, and on-floor support to move the process into engineering and GMP runs without losing yield or quality.

How to choose a Process Development CDMO?

The first filter is modality fit, and it is rarely close. A group that develops CHO-based monoclonal antibody processes every week is not the right home for an AAV gene therapy, an mRNA and LNP product, an autologous cell therapy, or a small-molecule API, and the reverse holds too. The unit operations, the scale-down models, and the analytical baggage differ completely. Match the CDMO to a process they run routinely, not one they are stretching to win.

After modality, the decision is mostly about whether the work will survive scale and transfer. The reason process development matters is that it feeds GMP manufacturing, so the partner that does it well is often the one that can also make your clinical material or hand off cleanly to the site that will. Ask how their process development connects to their GMP floor, how they document and de-risk tech transfer, and whether their scale-down model genuinely predicts the scale you need. Use this checklist when you compare suppliers:

  • Quality and GxP status: confirm where the non-GMP development work ends and GMP begins, and that the same supplier (or a clean transfer) carries you across that line. Process development itself is usually non-GMP, but it has to set up GMP-ready manufacturing.
  • Capacity and lead time: real availability and a realistic slot, plus turnaround on development runs. A great group booked solid for months can be slower than a good one with an open bench.
  • Modality and indication fit: routine experience with your specific process (mAb, viral vector, mRNA/LNP, cell therapy, peptide, ADC, or small-molecule API), with relevant case studies, not a general capabilities deck.
  • Region and regulatory track record: where the site sits, which agencies (FDA, EMA, PMDA) have inspected the connected GMP operation, and whether their process work has supported filings before.
  • Data quality: clean DoE design, traceable process data, sound scale-down models, and honest reporting of runs that failed, because the failures tell you more than the wins.
  • IP and confidentiality: clear ownership of process improvements and know-how, defined data and material transfer, and confidentiality terms you can live with on a process that is part of your asset's value.

Frequently asked questions

What is the difference between process development and manufacturing?
Process development defines and optimizes the process: it figures out the unit operations, operating ranges, and control strategy, and it proves the process scales and reproduces. Manufacturing then runs that defined process to make actual batches, under GMP once material is destined for patients. Development is mostly non-GMP and experimental; manufacturing is controlled and documented for release. The two are tightly linked, which is why many sponsors prefer a CDMO that can develop the process and then make the clinical material, so nothing is lost in a handoff between them.
Does process development need to be done under GMP?
Usually not. The point of process development is to define and de-risk the process before you commit to costly GMP runs, so the optimization, DoE, and scale-up work typically runs non-GMP. GMP applies once you make material that will go into a human and the testing that releases it. The practical sourcing question is where that line sits in your program and whether one supplier carries you across it, or a tech transfer to a GMP site is coming. Process development run well should leave you GMP-ready, even if the development work itself was not GMP.
What is upstream versus downstream process development?
For a biologic, upstream is everything that produces the molecule: cell culture or fermentation, media and feed strategy, bioreactor conditions, and the titer you can reach. Downstream is everything that purifies it: harvest and clarification, capture and polishing chromatography, viral inactivation and filtration, ultrafiltration and diafiltration, and final formulation. Upstream development chases productivity and consistent expression; downstream development chases purity, yield, and removal of aggregates, host-cell proteins, and other impurities. Both have to scale together, which is why they are usually developed in parallel by the same group.
How does tech transfer fit into process development?
Tech transfer is moving a defined process from where it was developed to where it will be run, whether that is from your lab to a CDMO, from development to the GMP floor, or from one site to another for scale. It is its own workstream: protocols, batch records, risk assessments, analytical method transfer, and on-floor support during the first runs. A weak transfer is where yield and quality quietly drop, so a CDMO whose development and manufacturing sit under one roof, or who documents transfer rigorously, lowers that risk. The fewer transfers your sourcing plan forces, the less exposure your clinical supply carries.
How long does process development take?
It depends heavily on modality and how mature your starting process is, so plan against your specific case rather than a generic number. A well-trodden monoclonal antibody or small-molecule API process is more predictable than a viral vector, mRNA and LNP, or cell therapy process, which tend to run longer and carry more uncertainty. Process development also rarely runs alone: analytical development moves in parallel because you cannot optimize what you cannot measure, and it feeds straight into engineering and GMP runs. Because it usually sits on the critical path into the clinic, locking a supplier and a slot early matters more than the headline duration.
Who owns the process know-how and IP we develop with a CDMO?
Settle this in writing before any work starts, because the optimized process is part of your asset's value. In a well-structured agreement the sponsor owns the process and improvements developed for the program, with clear terms on data and material transfer and on confidentiality. Watch for suppliers with platform technologies who may claim rights to platform-derived improvements, and confirm how the master cell bank, process records, and analytical methods get transferred to you or to your next site. Ambiguous ownership language is a red flag, since you may need to move this process to another manufacturer later.

Source Process Development with one contract

Compare transparent quotes from qualified Process Development CDMOs, then contract once. Free for buyers.

Compare quotes